Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adherence and patient experiences with oral anticancer agents
NL-OMON21194Active, not recruiting
- Sponsor
- VU University Medical Center
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenalidomide, thalidomide, dasatinib, imatinib, nilotinib and 8 more in cancer (13 arms), sponsored by VU University Medical Center. Primary endpoint: Adherence rate. Started Nov 2010; status: active, not recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON21194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21194.